Darryl B. McConnell
Boehringer Ingelheim (Austria)(AT)Institut Curie(FR)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Melanoma and MAPK Pathways, Protein Degradation and Inhibitors, Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis
Most-Cited Works
- → BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design(2019)560 cited
- → Pan-KRAS inhibitor disables oncogenic signalling and tumour growth(2023)458 cited
- → Drugging an undruggable pocket on KRAS(2019)420 cited
- → BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition(2020)393 cited
- → Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor(2016)221 cited
- → Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6(2017)202 cited
- → Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition